Axon Enterprise (NASDAQ:AXON) President Sells $6,349,850.00 in Stock

Axon Enterprise, Inc (NASDAQ:AXON) President Joshua Isner sold 13,000 shares of Axon Enterprise stock in a transaction on Friday, June 5th. The shares were sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the completion of the sale, the president directly owned 169,125 shares of the company’s stock, valued at approximately $82,609,106.25. The trade was a 7.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Axon Enterprise Stock Down 1.1%

AXON stock opened at $447.59 on Thursday. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $885.91. The company has a fifty day simple moving average of $409.55 and a 200 day simple moving average of $490.06. The firm has a market cap of $36.08 billion, a PE ratio of 179.76, a PEG ratio of 8.23 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The business had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.91 million. During the same quarter in the previous year, the business earned $1.47 EPS. Axon Enterprise’s quarterly revenue was up 33.7% compared to the same quarter last year. Sell-side analysts anticipate that Axon Enterprise, Inc will post 1.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on AXON. Royal Bank Of Canada reduced their price objective on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research note on Wednesday, February 25th. TD Cowen reduced their price objective on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a research note on Wednesday, April 8th. Barclays reduced their price objective on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Weiss Ratings raised shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Finally, Morgan Stanley set a $600.00 target price on shares of Axon Enterprise in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $712.75.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon’s Connected Devices business is showing renewed momentum, with revenue up 33% as demand accelerated for TASER 10, Axon Body 4, and platform solutions. That reinforces the company’s growth story and suggests upside if product adoption continues. AXON’s Connected Devices Growth Picks Up: More Upside to Come?
• Positive Sentiment: Analyst coverage remains favorable, with reports saying the average brokerage recommendation is a Buy / Moderate Buy and one major bank maintained a $705 price target. That kind of support can help investor confidence, especially after a recent selloff. Analyst Reiterates Buy on AppLovin, Maintains $705 Price Target on Axon-Driven Long-Term Growth Outlook
• Neutral Sentiment: Articles revisiting whether investors should trust brokerage ratings are more commentary than catalyst, so they are unlikely to move the stock on their own. AXON’s Connected Devices Growth Picks Up: More Upside to Come?
• Negative Sentiment: Insider sales by executive Patrick Smith and CRO Cameron Brooks may weigh on sentiment, even though the transactions were disclosed under pre-arranged trading plans. Investors often view insider selling cautiously when a stock has already been volatile. Patrick Smith Sells 20,000 Shares of Axon Enterprise (NASDAQ:AXON) Stock
• Negative Sentiment: Competitive pressure may be increasing as Motorola Solutions moves further into counter-drone and public safety technology, potentially challenging Axon’s future expansion in adjacent markets. Axon Enterprise Weighs Motorola Counter Drone Deal For Public Safety Future

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of AXON. Baillie Gifford & Co. lifted its position in Axon Enterprise by 1,198.7% during the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after acquiring an additional 1,516,099 shares during the last quarter. Edgewood Management LLC acquired a new position in Axon Enterprise during the 4th quarter worth $846,516,000. Wellington Management Group LLP lifted its position in Axon Enterprise by 326.9% during the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after acquiring an additional 1,179,038 shares during the last quarter. Norges Bank acquired a new position in Axon Enterprise during the 4th quarter worth $515,764,000. Finally, Vanguard Group Inc. lifted its position in Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after acquiring an additional 376,904 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.